Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PSC established by alkaline phosphatase \>1.5 times and/or two fold elevation of liver transaminases (AST and/or ALT) for at least 6 months duration.~* Cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction, beading, or narrowing consistent with PSC.~* Both genders.~* Age ≥ 18 years old and \< than 75 years old.~* Patient's informed consent for study participation.~Exclusion Criteria:~* Treatment with systematic antibiotics, azulfidine, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, tacrolimus, silymarin or prednisone in the preceding three months.~* Active drug or alcohol use.~* Prior history of allergic reactions to the antibiotics which will be used in the study.~* Any condition that, in the opinion of the investigator, would interfere with the patients' ability to complete the study safely or successfully.~* Evidence of decompensated liver disease such as recurrent variceal bleeding, refractory ascites or spontaneous hepatic encephalopathy.~* Anticipated need for transplantation in one year (Mayo survival model \<80% one-year survival without transplant).~* Findings highly suggestive of liver disease of other etiology such as chronic alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis, Wilson's disease, 1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis or secondary sclerosing cholangitis.~* Pregnancy or current lactation. Subjects becoming pregnant during the study will be withdrawn.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vancomycin 125 mg orally 4 times a day (Type: EXPERIMENTAL): The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
- Vancomycin 250 mg orally 4 times a day (Type: EXPERIMENTAL): None
- Metronidazole 250 mg orally 3 times a day (Type: EXPERIMENTAL): None
- Metronidazole 500 mg orally 3 times a day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).